#USA #New York #Class Action #Bronstein Gewirtz #Aardvark Therapeutics

Bronstein, Gewirtz & Grossman LLC Takes Action on Aardvark Therapeutics Class Action Lawsuit

Legal Action Against Aardvark Therapeutics, Inc.

A prominent law firm focused on investor rights, Bronstein, Gewirtz & Grossman, LLC, has initiated a class action lawsuit against Aardvark Therapeutics, Inc. (NASDAQ: AARD) as of August 20, 2026. This legal move seeks to recover damages for investors who may have suffered losses due to alleged violations of federal securities laws.

Case Background

The lawsuit covers all individuals and entities that acquired Aardvark securities, particularly those who purchased shares during the company’s initial public offering (IPO) on February 13, 2025, as well as those who invested between February 13, 2025, and May 14, 2026. During this period, the lawsuit claims that vital information regarding the company's drug, ARD-101, was misrepresented or omitted, leading to misleading public statements.

Allegations Against Aardvark

The complaints highlight the negligence in the preparation of the Offering Documents, which allegedly contained false statements or failed to provide crucial facts essential for investors’ decision-making. Specifically, the plaintiffs argue that:

- The safety of ARD-101 was misrepresented, suggesting it was safer than it actually is.
- The clinical, regulatory, and commercial prospects of the drug were overstated.
- Public statements made by the company were misleading throughout the defined Class Period.

These claims raise significant red flags about the transparency and integrity of Aardvark’s communications with the public and its investors.

How to Get Involved

Investors affected by these circumstances are urged to take action by visiting Bronstein, Gewirtz & Grossman LLC’s dedicated webpage for the case. The website, bgandg.com/cases/aardvark-therapeutics-inc-aard-class_action_lawsuit, serves as a resource for affected parties to understand their rights and the steps they can take to be involved in the litigation process.

Deadlines for Participation

Importantly, potential lead plaintiffs must act quickly, as the deadline to request the appointment as lead plaintiff is October 13, 2026. Regardless, even if individuals do not wish to serve as a lead plaintiff, they can still be a part of any recovery that results from the lawsuit.

No Upfront Costs

Bronstein, Gewirtz & Grossman LLC operates on a contingency fee basis, meaning that investors do not need to worry about legal fees unless the firm successfully recovers money on their behalf. This not only alleviates immediate financial burdens for the plaintiffs, but it also aligns the firm’s interests closely with those of the investors it represents.

Why Choose Bronstein, Gewirtz & Grossman LLC?

Recognized for its commitment to investor rights, Bronstein, Gewirtz & Grossman LLC has a long-standing track record of successfully advocating for shareholders in securities fraud cases and shareholder derivative suits. The firm has garnered hundreds of millions of dollars in recoveries for investors nationwide, reinforcing its reputation as a reliable ally in such legal matters.

Peretz Bronstein, the founding partner, emphasized the firm’s core mission: "Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace."

Conclusion

Aardvark Therapeutics’ investors are faced with significant implications following the initiation of this class action lawsuit. Those who may have experienced a financial setback due to misleading information from the company should consider joining the legal proceedings. For continued updates or inquiries, interested parties can connect through platforms such as LinkedIn, X, Facebook, or Instagram to stay informed.

For any immediate questions or assistance, investors can contact Peretz Bronstein or Nathan Miller of Bronstein, Gewirtz & Grossman LLC at 917-590-0911 or via email. Protecting investors brings a critical focus to corporate accountability and sets a precedent for future transparency.